Mixed
A modified-release combination of orlistat (120 mg) and acarbose (40 mg) produces significantly greater weight loss (mean -7.73%) compared to modified-release orlistat alone (-5.78%) or conventional orlistat (-5.13%) over 26 weeks.
Take the specific combination pill (EMP16) containing 120mg modified-release orlistat and 40mg modified-release acarbose daily with meals for 6 months. Follow a diet limiting fat to 30% of calories and focusing on low-glycemic foods. Expect roughly 7.7% body weight loss, which is significantly better than taking orlistat alone.
Mean relative weight loss was −7.73% for the EMP16 group as compared to −5.78% for the MR- O group and −5.13% for the Conv- O group (p < 0.01).
Why this rating
Randomized, double-blind, multi-arm phase 2 trial with 240 participants, though funded by the manufacturer.
Source
The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial
Ulf Holmbäck et al. · Obesity · 2025
DOI 10.1002/oby.24369
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →